Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price traded up 5.7% during trading on Thursday . The company traded as high as $13.66 and last traded at $13.85. 26,971 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 457,999 shares. The stock had previously closed at $13.10.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on BCAX shares. Wedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright raised their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $36.50.
Get Our Latest Report on BCAX
Bicara Therapeutics Price Performance
The business has a fifty day moving average price of $13.04.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.
Institutional Investors Weigh In On Bicara Therapeutics
Several hedge funds have recently added to or reduced their stakes in BCAX. California State Teachers Retirement System purchased a new position in shares of Bicara Therapeutics during the 4th quarter valued at about $25,000. Spire Wealth Management bought a new position in Bicara Therapeutics during the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets purchased a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $33,000. Finally, Summit Investment Advisors Inc. purchased a new position in Bicara Therapeutics in the 4th quarter worth $35,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
